Our Services

We conduct virtual human trials to reduce the cost and time of drug development.

Precise Disease Modeling

We build virtual human subject cohorts that are 100% malleable and tailorable to specific research needs, including customizable age ranges, gender distributions, and disease-linked biological variations.

  • Diverse Cohorts: Virtual subjects ranging from children and adolescents to the elderly.
  • System Integration: 25 integrated organoid-system responses tracked over simulated time.
  • Mechanistic Accuracy: Modeling functional biological systems including inflammation, metabolism, and DNA repair stress.
Precise Disease Modeling Animation

Accelerated Research

HumanQAI drastically compresses drug development timelines, delivering results in weeks rather than years, and significantly reducing the capital requirements for pre-clinical phases.

  • Rapid Delivery: Full written reports delivered in 4–8 weeks after project approval.
  • Efficiency Gains: Over 80% cost reduction and 90% compression of timelines for pre-IND and early-stage trials.
  • Actionable Data: Recommended next-phase dosing and comparative analysis (Placebo, Standard of Care).
Accelerated Laboratory Research

AI-Driven Insights

Leveraging aiHumanoid™ v11.9, we provide early-stage insights into toxicity, efficacy, and dose-response, enabling high-probability biomarker identification and de-risked therapeutic strategies.

  • Predictive Power: Safety and efficacy outcomes predicted with 95% confidence for primary and secondary endpoints.
  • Dose Optimization: Modeling 25–100% target range exposure levels using various routes of administration (PO, IV, inhaled, etc.).
AI-Driven Insights Analysis

Proven Results & Case Studies

Severe Autism Subset

Identified therapeutic targets and better treatment options in 4 weeks, validated through blinded identification of existing preclinical combinations.

Rare Disease (XPD)

Simulated >600 virtual subjects across 6 age groups. Identified top combinations with positive predictive value >90% in just 4 weeks.

Neurodevelopmental Disorders

Successfully identified optimal therapies for fatal NDDs, consistent with wet lab organoid results.

Oncology (TNBC)

aiOrganoid predictions for Triple Negative Breast Cancer were verified as consistent with actual treatment results obtained in wet lab models.